Company / Return on Equity (ROE)
Traws Pharma, Inc. Return on Equity (ROE) History
FY2015-FY2023 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Return on Equity (ROE)
-67.0%
FY2023
5-year range
-407.4% / -35.0%
FY2019-FY2023
Trend
-91.1%
vs FY2022
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Traws Pharma, Inc. reports negative total equity of -67.0% in FY2023. Negative equity can occur when accumulated losses exceed contributed capital, as reported in the balance sheet from the SEC filing.
Based on SEC 10-K filings.
-67.0% in FY2023 with a 5-year CAGR of +380.2%.
Improved from -407.4% to -67.0% over the past 2 years.
Return on Equity (ROE) over time
Growth rates
- 3-Year Change
- +118.8pp
- 5-Year Change
- +380.2pp
- 10-Year Change
- -
Key checks
Key Insights
- In FY2023, return on equity (roe) decreased 91.1% year-over-year.
- Peak return on equity (roe) was recorded in FY2022.
- Lowest return on equity (roe) in the period was in FY2015.
Company context
Key Data Points
- Altman Z-Score -42.17 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Return on Equity (ROE)Value | YoY GrowthYoY |
|---|---|---|
| FY2024 | - | - |
| FY2023 | -67.0% | -91.1% |
| FY2022 | -35.0% | +91.4% |
| FY2021 | -407.4% | -119.3% |
| FY2020 | -185.8% | +51.4% |
| FY2019 | -381.9% | +14.6% |
| FY2018 | -447.2% | - |
| FY2017 | - | - |
| FY2016 | -558.0% | +12.3% |
| FY2015 | -636.2% | -383.8% |
As of FY2023 · SEC 10-K · Updated Jun 28, 2026